Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

20063,478 citationsJournal Article

Authors

David M. Brown · Methodist Hospital

Peter K. Kaiser · Cleveland Clinic

Mark Michels · Retina Care Specialists

G. Soubrane · Université Paris-Est Créteil

Jeffrey S. Heier · Ophthalmic Consultants of Boston

Robert Y. Kim

Judy P. Sy

Susan Schneider

Abstract

Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).

Topics & Keywords

Retinal Diseases and Treatments Retinal and Optic Conditions Retinal Imaging and Analysis

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 14, pp. 1432-1444

DOI: 10.1056/nejmoa062655

Field-Weighted Citation Impact: 148.87

Command Palette